{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:17:01Z","timestamp":1740122221488,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T00:00:00Z","timestamp":1675468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T00:00:00Z","timestamp":1675468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s10620-022-07794-0","type":"journal-article","created":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T18:03:01Z","timestamp":1675533781000},"page":"2624-2634","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis"],"prefix":"10.1007","volume":"68","clinical-trial-number":[{"clinical-trial-number":"nct01465763","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01458951","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Gary R.","family":"Lichtenstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin L.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Salese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7144-6304","authenticated-orcid":false,"given":"Irene","family":"Modesto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haytham Mohamed","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chinyu","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,4]]},"reference":[{"key":"7794_CR1","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","volume":"389","author":"R Ungaro","year":"2017","unstructured":"Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel J-F. Ulcerative colitis. Lancet. 2017;389:1756\u20131770.","journal-title":"Lancet."},{"key":"7794_CR2","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","volume":"114","author":"DT Rubin","year":"2019","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114:384\u2013413.","journal-title":"Am J Gastroenterol."},{"key":"7794_CR3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1080\/17474124.2019.1604219","volume":"13","author":"M Salice","year":"2019","unstructured":"Salice M, Rizzello F, Calabrese C, Calandrini L, Gionchetti P. A current overview of corticosteroid use in active ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2019;13:557\u2013561.","journal-title":"Expert Rev Gastroenterol Hepatol."},{"key":"7794_CR4","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","volume":"68","author":"CA Lamb","year":"2019","unstructured":"Lamb CA, Kennedy NA, Raine T et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1\u2013106.","journal-title":"Gut."},{"key":"7794_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.rdc.2015.08.004","volume":"42","author":"J Youssef","year":"2016","unstructured":"Youssef J, Novosad SA, Winthrop KL. Infection risk and safety of corticosteroid use. Rheum Dis Clin North Am. 2016;42:157\u2013176.","journal-title":"Rheum Dis Clin North Am."},{"key":"7794_CR6","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/ajg.2012.218","volume":"107","author":"GR Lichtenstein","year":"2012","unstructured":"Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infection and mortality in patients with Crohn\u2019s disease: more than 5 years of follow-up in the TREAT\u2122 registry. Am J Gastroenterol. 2012;107:1409\u20131422.","journal-title":"Am J Gastroenterol."},{"key":"7794_CR7","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723\u20131736.","journal-title":"N Engl J Med."},{"key":"7794_CR8","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/apt.16712","volume":"55","author":"WJ Sandborn","year":"2022","unstructured":"Sandborn WJ, Lawendy N, Danese S et al. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment. Aliment Pharmacol Ther. 2022;55:464\u2013478.","journal-title":"Aliment Pharmacol Ther."},{"key":"7794_CR9","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1093\/ecco-jcc\/jjaa233","volume":"15","author":"KL Winthrop","year":"2021","unstructured":"Winthrop KL, Loftus EV, Baumgart DC et al. Tofacitinib for the treatment of ulcerative colitis: analysis of infection rates from the ulcerative colitis clinical programme. J Crohns Colitis. 2021;15:914\u2013929.","journal-title":"J Crohns Colitis."},{"key":"7794_CR10","doi-asserted-by":"publisher","first-page":"S296","DOI":"10.1093\/ecco-jcc\/jju027.552","volume":"9","author":"J-F Colombel","year":"2015","unstructured":"Colombel J-F, Loftus EV Jr, Siegel CA et al. P433 Efficacy of vedolizumab with concomitant corticosteroid or immunomodulator use in patients with ulcerative colitis from GEMINI 1 [abstract]. J Crohns Colitis. 2015;9:S296\u2013S297.","journal-title":"J Crohns Colitis."},{"key":"7794_CR11","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.cgh.2020.06.036","volume":"19","author":"DM Faleck","year":"2021","unstructured":"Faleck DM, Shmidt E, Huang R et al. Effect of concomitant therapy with steroids and tumor necrosis factor antagonists for induction of remission in patients with Crohn\u2019s disease: a systematic review and pooled meta-analysis. Clin Gastroenterol Hepatol. 2021;19:238-245.e234.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"7794_CR12","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","volume":"134","author":"M Toruner","year":"2008","unstructured":"Toruner M, Loftus EV Jr, Harmsen WS et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929\u2013936.","journal-title":"Gastroenterology."},{"key":"7794_CR13","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1136\/gut.2008.163642","volume":"58","author":"H Fidder","year":"2009","unstructured":"Fidder H, Schnitzler F, Ferrante M et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009;58:501\u2013508.","journal-title":"Gut."},{"key":"7794_CR14","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1038\/ajg.2009.322","volume":"104","author":"J Marehbian","year":"2009","unstructured":"Marehbian J, Arrighi HM, Hass S, Tian H, Sandborn WJ. Adverse events associated with common therapy regimens for moderate-to-severe Crohn\u2019s disease. Am J Gastroenterol. 2009;104:2524\u20132533.","journal-title":"Am J Gastroenterol."},{"key":"7794_CR15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1093\/rheumatology\/kep325","volume":"49","author":"CG Grijalva","year":"2010","unstructured":"Grijalva CG, Kaltenbach L, Arbogast PG, Mitchel EF Jr, Griffin MR. Initiation of rheumatoid arthritis treatments and the risk of serious infections. Rheumatology (Oxford). 2010;49:82\u201390.","journal-title":"Rheumatology (Oxford)."},{"key":"7794_CR16","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1136\/ard.2011.151043","volume":"70","author":"A Strangfeld","year":"2011","unstructured":"Strangfeld A, Eveslage M, Schneider M et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis. 2011;70:1914\u20131920.","journal-title":"Ann Rheum Dis."},{"key":"7794_CR17","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1136\/ard.2010.144741","volume":"70","author":"WG Dixon","year":"2011","unstructured":"Dixon WG, Kezouh A, Bernatsky S, Suissa S. The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study. Ann Rheum Dis. 2011;70:956\u2013960.","journal-title":"Ann Rheum Dis."},{"key":"7794_CR18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.5009\/gnl18304","volume":"13","author":"H Soh","year":"2019","unstructured":"Soh H, Chun J, Han K et al. Increased risk of herpes zoster in young and metabolically healthy patients with inflammatory bowel disease: a nationwide population-based study. Gut Liver. 2019;13:333\u2013341.","journal-title":"Gut Liver."},{"key":"7794_CR19","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1093\/ibd\/izy150","volume":"24","author":"JF Colombel","year":"2018","unstructured":"Colombel JF. Herpes zoster in patients receiving JAK inhibitors for ulcerative colitis: mechanism, epidemiology, management, and prevention. Inflamm Bowel Dis. 2018;24:2172\u20132182.","journal-title":"Inflamm Bowel Dis."},{"key":"7794_CR20","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.cgh.2006.09.019","volume":"4","author":"G Gupta","year":"2006","unstructured":"Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:1483\u20131490.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"7794_CR21","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/apt.12182","volume":"37","author":"MD Long","year":"2013","unstructured":"Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:420\u2013429.","journal-title":"Aliment Pharmacol Ther."},{"key":"7794_CR22","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.cgh.2017.12.052","volume":"16","author":"N Khan","year":"2018","unstructured":"Khan N, Patel D, Trivedi C et al. Overall and comparative risk of herpes zoster with pharmacotherapy for inflammatory bowel diseases: a nationwide cohort study. Clin Gastroenterol Hepatol. 2018;16:1919\u20131927.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"7794_CR23","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1093\/ibd\/izy131","volume":"24","author":"KL Winthrop","year":"2018","unstructured":"Winthrop KL, Melmed GY, Vermeire S et al. Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis. 2018;24:2258\u20132265.","journal-title":"Inflamm Bowel Dis."},{"key":"7794_CR24","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.gastro.2020.05.032","volume":"159","author":"EJ Brenner","year":"2020","unstructured":"Brenner EJ, Ungaro RC, Gearry RB et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology. 2020;159:481\u2013491.","journal-title":"Gastroenterology."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-022-07794-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-022-07794-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-022-07794-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T04:28:03Z","timestamp":1684211283000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-022-07794-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,4]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["7794"],"URL":"https:\/\/doi.org\/10.1007\/s10620-022-07794-0","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"type":"print","value":"0163-2116"},{"type":"electronic","value":"1573-2568"}],"subject":[],"published":{"date-parts":[[2023,2,4]]},"assertion":[{"value":"8 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GRL has received research support and\/or funding from Celgene, Janssen Ortho Biotech, Pfizer Inc, Takeda, and UCB; consultancy fees from AbbVie, American Regent, Celgene, Cellceutix, Eli Lilly, Endo Pharmaceuticals, Ferring Pharmaceuticals, Gilead Sciences, Janssen Ortho Biotech, Merck, Morphic Therapeutics, Pfizer Inc, Prometheus Laboratories Inc, Romark, Salix\/Valeant, Shire, Takeda, and UCB; honoraria from the American College of Gastroenterology, American Regent, Gastroenterology and Hepatology, Merck, Romark, Springer Science and Business Media, and Up-To-Date; and royalties from Professional Communications Inc and SLACK Inc. BLC has been an advisory board member for AbbVie; has received consultancy or speaker fees from AbbVie; and received support\/and or funding from Celgene, Bristol-Myers Squibb, Cornerstones, Pfizer Inc, Sublimity Therapeutics, Takeda, TARGET RWE, and Vindico. LS, IM, WW, GC, HMA, and CS are employees and stockholders of Pfizer Inc. LP-B has received honoraria from AbbVie, Allergan, Alma, Amgen, Arena, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Enterome, Ferring Pharmaceuticals, Genentech, Gilead Sciences, Hikma, Index Pharmaceuticals, Janssen, MSD, Nestl\u00e9, Pfizer Inc, Pharmacosmos, Roche, Samsung Bioepis, Sandoz, Sterna, Takeda, and Tillotts; grants from AbbVie, MSD, and Takeda; and is a stockholder of CTMA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All studies were conducted in compliance with the Declaration of Helsinki and the International Council for Harmonisation Good Clinical Practice Guidelines. Study protocols were approved by the Institutional Review Board and\/or Independent Ethics Committee at each of the investigational centers participating in the studies, or a central Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}